FDA granted a Breakthrough Therapy Designation to venetoclax in combination with rituximab for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.
FDA granted Priority Review to lenvatinib for the treatment of patients with unresectable advanced or metastatic renal cell carcinoma in combination with everolimus following one prior vascular endothelial growth factor-targeted therapy. FDA previously granted lenvatinib Breakthrough Therapy designation for this investigational indication. “With the FDA’s acceptance of this supplemental application, we are one step closer... […]
Debiopharm International SA announced a collaboration in order to supply triptorelin pamoate 3.75 mg one-month formulation for patients suffering from salivary gland cancer participating in a clinical study sponsored by the European Organisation for Research and Treatment of Cancer.
Health Canada granted conditional approval of Blincyto (blinatumomab) for the treatment of adults with Philadelphia chromosome-negative relapsed or refractory B precursor acute lymphoblastic leukemia.
MD Anderson Cancer Center and DelMar Pharmaceuticals Inc. entered into a collaboration to accelerate the clinical development of DelMar's lead anti-cancer candidate, VAL-083, for the treatment of glioblastoma multiforme.
Eisai submitted a Marketing Authorization Application to the European Medicines Agency for the use of lenvatinib in combination with everolimus to treat people with unresectable advanced or metastatic renal cell carcinoma who have received one prior vascular endothelial growth factor-targeted therapy.
Sorrento Therapeutics Inc. formed a partnership with the Karolinska Institutet in Stockholm, Sweden, to perform immuno-oncology research and to develop new natural killer cell-based therapies.
FDA granted Priority Review to venetoclax for the treatment of chronic lymphocytic leukemia in adults who have received at least one prior therapy, including patients with 17p deletion.
FDA granted Breakthrough Therapy Designation to an epidermal growth factor receptor mutant-specific tyrosine kinase inhibitor, BI 1482694 (HM61713).
Guardant Health and Mirati Therapeutics Inc. entered into a collaboration for the development of a circulating tumor DNA assay for Mirati's kinase inhibitor, glesatinib.
